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Abstract
Objective: The aim of this study is to compare actual driving performance and skills
related to driving of patients using benzodiazepine anxiolytics or hypnotics for at
least 6 months to that of healthy controls.
Methods: Participants were 44 long-term users of benzodiazepine and
benzodiazepine-related anxiolytics (n = 12) and hypnotics (n = 32) and 65 matched
healthy controls. Performance was assessed using an on-the-road driving test mea-
suring standard deviation of lateral position (SDLP, in cm) and a battery of
neurocognitive tasks. Performance differences between groups were compared with
a blood alcohol concentration of 0.5 mg/ml to determine clinical relevance.
Results: Compared with controls, SDLP was significantly increased in hypnotic users
(+1.70 cm) but not in anxiolytic users (+1.48 cm). Anxiolytic and hypnotic users
showed significant and clinically relevant impairment on neurocognitive task measur-
ing executive functioning, vigilance, and reaction time. For patients using hypnotics
for at least 3 years, no significant driving impairment was observed.
Conclusion: Impairing effects of benzodiazepine hypnotics on driving performance
may mitigate over time following longer term use (i.e. 3 years or more) although
neurocognitive impairments may remain.
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1 | INTRODUCTION
Benzodiazepines are frequently prescribed to treat anxiety- and
sleep-related disorders (Cloos & Ferreira, 2009; Morin, Jarvis, &
Lynch, 2007). It is well known that these drugs may cause psychomo-
tor and cognitive impairments that interfere with daily activities such
as operating a vehicle (Dassanayake, Michie, Carter, & Jones, 2011;
Vermeeren, 2004; Verster, Veldhuijzen, & Volkerts, 2005).
Epidemiological studies showed that benzodiazepine use is asso-
ciated with an increase in risk of becoming involved in a traffic acci-
dent (Dassanayake et al., 2011; Neutel, 1995; Neutel, 1998; Smink,
Egberts, Lusthof, Uges, & De Gier, 2010). Crash risk was highest
directly following treatment initiation but gradually decreased after
prolonged exposure (Neutel, 1995). Likewise, the risk of becoming
involved in a traffic accident was found to be lower for repeated users
of benzodiazepines in comparison with new users (Neutel, 1998). Yet,
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despite indications of tolerance, crash risk was still shown to be signif-
icantly higher in drivers after 1 year of benzodiazepine usage (Hansen,
Boudreau, Ebel, Grossman, & Sullivan, 2015; Hemmelgarn, Suissa,
Huang, Jean-Francois, & Pinard, 1997).
In experimental studies, the clinical relevance of benzodiazepine-
induced performance impairment is established by comparison with
alcohol, given its well-documented dose-dependent association with
crash risk (Blomberg, Peck, Moskowitz, Burns, & Fiorentino, 2009;
Borkenstein, Crowther, & Shumate, 1974). Most experimental
studies focussed on performance impairments observed after single
doses of benzodiazepines when administered to healthy volunteers
(Roth, Eklov, Drake, & Verster, 2014; Vermeeren, 2004; Vermeeren,
Leufkens, & Verster, 2009; Verster, Veldhuijzen, Patat, Olivier, &
Volkerts, 2006). Results showed that after a single day or night of
treatment, benzodiazepines produce moderate or severe impairment
of driving performance equivalent to driving under the influence of a
blood alcohol concentration (BAC) of 0.5 mg/ml or more. Differences
between benzodiazepines with regard to their level of impairment
exist and mainly depend on dosage, time of administration, and drug
half-life (Leufkens, Lund, & Vermeeren, 2009; Vermeeren, 2004; Ver-
meeren et al., 2009; Verster, Veldhuijzen, & Volkerts, 2004).
Data from experimental studies on drug effects on driving and
neurocognitive function have also been used to classify fitness to
drive. Such classification systems (de Gier, Alvarez, Mercier-Guyon, &
Verstraete, 2009; Ravera et al., 2012) express drug-induced impair-
ment in BAC equivalents. Classifications that are commonly used to
define drug effects on driving, in relationship to alcohol, are no/minor
influence (Category 0/I, BAC < 0.5 mg/ml), moderate influence
(Category II, 0.5 mg/ml ≤ BAC ≤ 0.8 mg/ml), and severe influence
(Category III, BAC > 0.8 mg/ml). A limitation of existing drug categori-
zation systems is their lack of information about the effect of long-
term drug usage on driving performance. Current classifications are
mainly based on acute effects of single doses or short-term treatment
in healthy volunteers. Consequently, most benzodiazepines are put in
Category III because their acute effects on performance are usually
severe. Yet it is known that tolerance to benzodiazepine impairment
might develop after repeated administration in healthy volunteers
(Ghoneim, Mewaldt, Berie, & Hinrichs, 1981; Pomara et al., 1998) and
patients (O'Hanlon, Vermeeren, Uiterwijk, Van Veggel, & Swijgman,
1995; van Laar, Volkerts, & van Willigenburg, 1992).
Nevertheless, driving performance may not completely normalize,
as suggested by impairment found in a range of neuropsychological
functions of long-term benzodiazepine users (Barker, Greenwood,
Jackson, & Crowe, 2004; Crowe & Stranks, 2017). The severity and
relevance of such impairment with respect to patients' driving perfor-
mance is not clear however. The classification of benzodiazepines in
Category III, irrespective of duration of use, may be overly conserva-
tive for drivers who have been receiving long-term treatment, limiting
their mobility. As a partial solution, taking duration of use into
account, current Dutch laws state that benzodiazepine users are unfit
to drive when treated for less than 3 years but can request an individ-
ual driver fitness evaluation after more than 3 years of stable usage
(Ministry of Infrastructure and Water Management, 2000). The
criterion of 3 years seems rather arbitrary, because there is no clear
scientific support for this particular cut-off point. As far as we know,
there are no published studies comparing driving performance of
long-term benzodiazepine users before and after 3 years of use.
The primary objective of the present study was to evaluate driv-
ing performance of long-term users of benzodiazepine anxiolytics and
long-term users of hypnotics separately, as compared with that of a
normative control group consisting of healthy volunteers. Only users
of benzodiazepines classified as Category III were included. Long-term
usage was defined as longer than 6 months. The secondary objective
was to evaluate driving performance separately for patients who had
been using treatment for less than 3 years and those whose use
exceeded 3 years. Driving performance was assessed by a standard-
ized highway driving test in actual traffic and various neurocognitive
tests related to driving.
2 | METHODS
2.1 | Design
The study was designed as a multicentre trial (Universities of Maas-
tricht, Utrecht and Groningen, the Netherlands) comparing groups of
long-term users of benzodiazepines with healthy controls. Patients
treated with benzodiazepines anxiolytics and hypnotics were analysed
separately, because of the difference between these groups in time of
drug intake relative to time of driving. It is known that the impairing
effects of benzodiazepines on driving decrease with increased time
after intake. Hypnotics are taken at bedtime, and driving occurs the
next day, 8 hr or more after administration. In contrast, anxiolytics are
administered during the day, and driving is likely to occur within 8 hr
of administration. A combination of self-reported indication and usual
time of drug administration was used to classify a patient as user of
hypnotics or anxiolytics.
To explore the potential difference in impairment before and after
3 years of use, hypnotic users were subdivided into two groups based
on duration of treatment, that is, long-term use between 6 months–
3 years (LT3−) and long-term use >3 years (LT3+). Anxiolytic users
could not be divided based on treatment duration due to the low sam-
ple size of this group.
2.2 | Participants
Patients were recruited via patient organizations, hospitals, and practi-
tioners affiliated with UPPER (Koster, Blom, Philbert, Rump, & Bouvy,
2014) and regional advertisement. Controls were recruited via flyers
and advertisement in local newspapers.
Study participants were informed about the study's goal, proce-
dures, and potential hazards. The Medical Ethics Committee of Maas-
tricht University and the Maastricht Academic Hospital approved the
study. Furthermore, the study was conducted in agreement with the
code of ethics on human experimentation established by the
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Declaration of Helsinki (1964), amended in Edinburgh (2000), Seoul
(2008), and Fortaleza (2013). Written informed consent was obtained
from each volunteer before enrolment. Volunteers received a financial
compensation for their participation in the study.
2.2.1 | Patients
A group of 44 long-term users of benzodiazepines or benzodiazepine-
like drugs (i.e., Z drugs) was recruited (12 users of anxiolytics
and 32 users of hypnotics). All patients used category III drugs that
are expected to severely affect fitness to drive. These included alpraz-
olam, bromazepam, brotizolam, diazepam, lorazepam, lormetazepam,
midazolam, nitrazepam, oxazepam, temazepam, zolpidem, or
zopiclone. Initial screening was based on a medical history question-
naire that was evaluated by a clinician.
The following inclusion criteria had to be met: use of a category
III benzodiazepine or benzodiazepine-like drug over a period of at
least 6 months with a frequency of at least two times a week
(≈90 days/year), possession of a valid driver's license for at least
3 years, driving an average of at least 500 km/year, normal or
corrected to normal vision, and body mass index between 17 and
35 kg/m2. Although Dutch law deems benzodiazepine users who have
been treated for less than 3 years are unfit to drive, many of them
drive a motor vehicle simply because they are unaware of this legal
provision and because this provision is not actively enforced by the
Dutch government either. Patients were excluded if they used con-
comitant medication classified as International Council on Alcohol,
Drugs and Traffic Safety (ICADTS) Category III. Concomitant medica-
tion classified as ICADTS Category 0/I was allowed, whereas ICADTS
Category II was evaluated by a clinician on individual bases. Additional
exclusion criteria were alcohol use >21 glasses per week, smoking
>20 cigarettes a day, and use of illegal drugs.
Before test days, patients took their anxiolytic or hypnotic medi-
cation as usual, that is, in the evening or morning before testing.
Patients usual dosing regimen were established at screening and mon-
itored by self-report on the practice and test day.
2.2.2 | Controls
A group of 65 healthy volunteers was recruited with comparable
age, gender distribution, and driving experience as patients. Inclu-
sion criteria were a valid driver's license for at least 3 years, driving
an average of 3,000 km/year, normal or corrected to normal vision,
and a body mass index between 19 and 29 kg/m2. Exclusion
criteria were diagnosed with a neurological disorder or sleeping dis-
order, alcohol use >21 glasses per week, smoking >10 cigarettes a
day, and use of illegal drugs and psychoactive medication
(e.g., antidepressants, benzodiazepines, antiepileptics, anticonvul-
sants, antihistamines, and opioids).
2.3 | Driving test
In the standardized on-the-road highway driving test (Figure 1;
O'Hanlon, 1984; Ramaekers, 2017; Verster & Roth, 2011), volun-
teers drive a specially instrumented car over a 100 km (61 miles)
primary highway circuit accompanied by a licensed driving instructor
having access to dual controls. The volunteers' task is to maintain a
constant speed of 95 km/hr (58 miles/hr) and a steady lateral posi-
tion between the delineated boundaries of the slower right hand
F IGURE 1 Standard highway driving test. Left: Volunteers drive a specially instrumented vehicle for about 1 hr over a 100-km primary
highway circuit, accompanied by a licensed driving instructor having access to dual controls. The volunteer's task is to drive with a steady lateral
position between the delineated boundaries of the slower (right) traffic lane, while maintaining a constant speed of 95 km/hr. The lateral position
of the car relative to the middle line, between the left and right traffic lane, is continuously measured by means of a camera that is mounted on
the roof of the car. Right: schematic drawing of the highway driving test. The standard deviation of lateral position (SDLP) is an index of road
tracking error or “weaving.” Drugs that induce sleepiness or sedation cause loss of vehicle control, leading to increased road tracking error
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traffic lane. The vehicle's speed and lateral position relative to the
left lane delineation is continuously recorded. These signals are digi-
tally sampled at 4 Hz and edited offline to remove data recorded
during overtaking manoeuvres or disturbances caused by roadway
or traffic situations. The remaining data yield the standard deviation
of lateral position (SDLP) and speed for each successive 5-km seg-
ment and, as the square root of pooled variance over all segments,
for the test as a whole. The primary outcome variable is the SDLP
(in cm), which is a measure of road tracking error or “weaving.”
Drug-induced impairments in the standardized highway driving test
have been compared with that of a well-known benchmark drug
(i.e., alcohol) that is known to jeopardize traffic safety and shows a
clear exponential dose-dependent relationship with accident crash
risk (Blomberg et al., 2009; Borkenstein et al., 1974). The clinical rel-
evance of performance changes in the highway driving test has pre-
viously been determined by establishing the relationship between
BAC and SDLP (Louwerens, Gloerich, DeVries, Brookhuis, &
O'Hanlon, 1987). A recent meta-analysis of nine alcohol calibration
studies revealed a mean increment in SDLP of 2.5 cm while operat-
ing the vehicle at a BAC of 0.5 mg/ml, which has been defined as
the minimal cut-off value to represent clinically relevant impairment
(Jongen et al., 2017). The highway driving test has been used in
more than 100 studies and has proven sensitivity to alcohol, benzo-
diazepines, and many other sedating drugs (Ramaekers, 2017; Roth
et al., 2014; Vermeeren, 2004).
2.4 | Neurocognitive tests
2.4.1 | Trail Making Test
The Trail Making Test (TMT) is a paper-and-pencil test measuring
selective and divided attention, as well as executive functions (Reitan,
1958). The test comprises two parts. In Part A, the task of the volun-
teer is to connect, as fast as possible, 25 circles that contain the Num-
bers 1 to 25, by means of connecting the circles in ascending order. In
Part B, the 25 circles contain letters (A to L) and numbers (1 to 13).
Volunteers are required to connect, as fast as possible, the 25 circles
in an alternately ascending fashion (i.e., 1-A-2-B-3-C, and so on). The
maximum time allowed for part A is 5 min, and for part B, it is 6 min.
The outcome measures for Parts A and B is the time (in seconds)
needed to complete the task.
2.4.2 | Digit Symbol Substitution Test
The Digit Symbol Substitution Test (DSST) is a paper-and-pencil
test measuring executive attention and processing speed (Wechsler,
1958). Volunteers are presented with rows of digits (1 to 9) and
have to respond by writing the corresponding symbol in a blank
space, according to a key presented at the top of the paper. The
primary outcome measure is the number of correctly substituted
digits in 90 s.
2.4.3 | Adaptive Tachistoscopic Traffic
Perception Test
The Adaptive Tachistoscopic Traffic Perception Test (ATTPT) assesses
visual orientation ability, visual observational ability, speed of percep-
tion, and skills in obtaining a traffic overview (Schuhfried, 2009). Vol-
unteers are presented with pictures of traffic situations for a very
short duration. After each picture, volunteers are required to indicate
what was in the picture, by choosing from five answer options
(i.e., cars, cyclists, pedestrians, traffic signs, and/or traffic lights). Pic-
tures are presented adaptively, meaning that the difficulty of the pic-
tures is adapted to the abilities of the volunteer (i.e., volunteers, who
perform poorly and receive pictures containing less complex traffic
situations; vice versa for volunteers who perform well). The primary
outcome is the number of correct answers. Time to complete the task
is 10 min.
2.4.4 | Reaction Test
The Reaction Test (RT) assesses reaction time and motor time in
response to simple and complex visual or acoustic signals (Prieler,
2008). Before the test, volunteers are instructed to lay their index fin-
ger on a pressure-sensitive key (i.e., rest key). During the test, volun-
teers are required to press a target key, with their index finger,
whenever a target stimulus is presented. After pressing the target key,
they must return their index finger immediately to the rest key. By
means of using a rest key and target key, it is possible to distinguish
between reaction time (time between the presentation of the target
stimulus and the moment the index finger is removed from the rest
key) and motor time (the time between releasing the rest key and
pressing the target key). The current experiment uses three versions
of the reaction test, that is, S1, in which volunteers have to respond
whenever a yellow circle is shown on screen; S2, in which volunteers
have to respond whenever they hear a tone; and S3, in which volun-
teers have to respond whenever they see a yellow circle on screen
and a hear a tone in combination; all other stimuli combinations are to
be ignored. Time to complete all three versions of this task is 10 min.
Outcome measures for these tests are reaction time and motor time.
2.4.5 | Determination Test
The Determination Test (DT) measures reactive stress tolerance,
divided attention, and mental flexibility (Neuwirth & Benesch, 2007).
The test measures the ability to sustain attention over a period of
approximately 10 min. Volunteers are presented with visual stimuli of
varying colour and sounds with a different pitch, in a serial order. For
each stimulus, a predefined button has to be pressed. The presenta-
tion of stimuli is adaptive to the reaction speed of the volunteer,
meaning that the interstimulus interval is shortened when volunteers
make correct and fast responses and is slowed down when volunteers
make mistakes or make slow responses. During the task, volunteers
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are presented with the following stimuli and have to press the follow-
ing corresponding buttons: (a) visual coloured circles (white, yellow,
red, green, and blue), each presented colour has a matching coloured
key on the keyboard; (b) auditory signals (low pitch and high pitch),
each auditory signal has its own response key on the keyboard; and
(c) motor signals (displayed as a white rectangle on the left or right
side of the bottom of the screen), each motor signal required the vol-
unteer to press a response pad with his right or left foot, depending
on the position of the white rectangle on screen. The outcome mea-
sure is the average reaction time of all responses made.
2.4.6 | Risk-Taking Test Traffic
The Risk-Taking Test Traffic (RTTT) measures risk-taking behaviour in
potentially dangerous driving situations (Hergovich, Bognar,
Arendasy, & Sommer, 2005). Volunteers are presented with 24 items
(i.e., video clips) that show diverse driving situations, which are
described in words before they are shown on screen. Each driving sit-
uation is shown twice. During the first time, volunteers observe the
entire driving situation. During the second time, volunteers are
required to press a key on the keyboard, indicating the distance from
the potential hazard at which the driving manoeuvre that has just
been described becomes critical or dangerous (i.e., the point at which
the volunteer would no longer perform the manoeuvre). The first item
of the 24 items serves as a practice item. Time to complete the task is
approximately 15 min. The variable “willingness to take risk in driving
situations” is measured by obtaining the distance between the
moment of a potential hazard, measured in hundreds of a second, and
the moment the volunteer presses the key indicating that the poten-
tial hazard becomes critical or potentially dangerous. This distance is a
measure of subjectively accepted level of risk. Higher scores indicate
higher levels of subjectively accepted risk.
2.4.7 | Psychomotor Vigilance Test
The Psychomotor Vigilance Test (PVT) is based on a simple visual
reaction time test (Dinges & Powell, 1985). The test measures the
ability to sustain attention over a period of approximately 10 min. Vol-
unteers are required to respond to a visual stimulus presented at a
variable interval (2–10 s) by pressing a button with the dominant
hand. The visual stimulus is the presentation of a counter that starts
running from 0 to 60 s at 1-ms intervals. Volunteers are required to
respond to this visual counter as soon as they perceive it on screen by
pressing the corresponding button. If a response is made, the counter
stops, stays on screen for 500 ms as visual feedback for the volunteer,
and disappears. During this period, a variable interval is presented,
and afterwards, the next counter appears on screen. This cycle
repeats until 100 stimuli have been presented on screen. If a response
has not been made within 60 s, the clock resets and the counter
restarts. Primary outcome measures are mean response speed and
number of lapses (defined as responses with RT ≥ 500 ms; Basner &
Dinges, 2011). Performance on the PVT has been calibrated for dose
effects of alcohol and one night of sleep deprivation (Jongen, Perrier,
Vuurman, Ramaekers, & Vermeeren, 2015; Jongen, Vuurman,
Ramaekers, & Vermeeren, 2014).
2.5 | Questionnaires
2.5.1 | Beck's Depression Inventory
The Beck Depression Inventory (BDI; Beck, Steer, & Carbin, 1988) is a
21-item self-report questionnaire measuring depression-related
symptomology. Answer options for each question range from 0 to
3. The obtained total score for the BDI serves as an indicator for the
presence of depression-related symptoms, ranging from 0 to 63.
Higher total scores indicate the presence of more symptoms of
depression.
2.5.2 | State–Trait Anxiety Index—Trait
The State–Trait Anxiety Index—Trait (STAI-T; Spielberger, Gorsuch, &
Lushene, 1970) is the trait dimension of the 40-item self-reported
STAI questionnaire. The STAI-T contains 20 questions that measure
trait anxiety (i.e., how individuals feel in general). Answer options for
each questions range from 1 to 4, with total scores ranging from 20 to
80. Higher total scores indicate more anxiety-related symptoms.
2.5.3 | Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds, Monk,
Berman, & Kupfer, 1989) is a self-report questionnaire that assesses
the quality and patterns of sleep over the last month, by rating seven
sleep-related domains: subjective sleep quality, sleep latency, sleep
duration, habitual sleep efficiency, sleep disturbance, use of medica-
tion, and daytime disturbance. A summary score ranging from 0 to
21 can be derived, with higher scores indicating poorer sleep quality.
A summary score ≥5 indicates a poor sleeper.
2.5.4 | Groningen Sleep Quality Scale
The Groningen Sleep Quality Scale (GSQS; Mulder-Hajonides van der
Meulen, Wijnberg, Hollander, De Diana, & van den Hoofdakker, 1980)
is a 14-item self-report scale that assess subjective quality of sleep
during the preceding night. Summary scores range from 0 to 14, with
higher scores indicating poorer sleep quality. A total score ≥6 indi-
cates disturbed sleep.
2.6 | Procedure
All volunteers completed a practice session and a test session, on two
separate days with an interval of 1 week between both days. Volun-
teers started at 8:30 a.m., 10:30 a.m., or 12:30 p.m. based on individ-
ual convenience, but the starting time was kept constant on practice
and test days. On Day 1 (practice day), volunteers filled out three
questionnaires (BDI, PSQI, and STAI-T) and were familiarized with the
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test procedures. Volunteers were individually trained to perform the
driving test and all the neurocognitive tests. On Day 2 (test day), vol-
unteers first completed the GSQS, followed by the first part of the
neurocognitive test battery (TMT, DSST, ATTPT, RT, and DT). After a
15-min break, volunteers completed the second part of the
neurocognitive test battery (RTTT and PVT). Finally, volunteers were
transported to the start of the highway to start the 1-hr driving test.
The total duration of a test day was approximately 4 hr (Figure 2).
2.7 | Statistical analysis
Statistical power to detect a clinically relevant mean difference in
SDLP of 2.5 cm between patients and controls was as follows: anxio-
lytic users versus controls, β = .58; hypnotic users versus controls,
β = .85; hypnotic LT3− users versus controls, β = .50; and hypnotic
LT3+ users versus controls, β = .78. Assumptions for these power cal-
culations were an alpha of .05 and a between-subject variance in
SDLP of 4.3 cm (Jongen et al., 2017).
Matching variables (age, gender, and driving experience) were
included as covariates in an analysis of covariance model. If none of
the matching variables showed a significant influence on group com-
parisons with SDLP or a neurocognitive parameter, patient perfor-
mance was compared with that of the entire group of controls
(n = 65). Alternatively, if one (or more) matched variable did show a
significant influence on a between-group comparison, only individually
matched controls were included. The determination of the influence
of matching variables was performed for SDLP and each
neurocognitive parameter separately.
Next, noninferiority analyses were used to determine whether
the 95% confidence interval (CI) of performance differences between
patients and controls exceeded the criterion level of clinical relevance,
that is, an equivalent performance change as seen at a BAC of
0.5 mg/ml. When evaluating the 95% CI of differences between
groups, three interpretations are possible (Figure 3). Patients' perfor-
mance was considered not impaired (i.e., noninferior) when the upper
limit of the 95% CI of the difference from controls was below the
alcohol criterion for impairment. Patients' performance was
considered impaired (i.e., inferior) when the lower limit of the 95% CI
of the difference from controls was above zero and the upper limit
exceeded the alcohol criterion for impairment. When the 95% CI of
the difference from controls included both zero and the alcohol crite-
rion for impairment, the results were considered inconclusive. The
noninferiority limit for the on-the-road driving test (Figure 4) was
obtained from Jongen et al. (2017).
Clinical relevance of impairment of neurocognitive performance
was also based on direct comparison impairing the effects of alcohol
at a BAC of 0.5 mg/ml. In a separate study (Verster et al., 2016), an
alcohol calibration was performed to determine which neurocognitive
parameters were able to detect impairment at a BAC of
0.5 mg/ml. Results of the calibration study showed that the only
parameters sensitive for the impairing effects of alcohol were TMT-A,
DSST, RT-S1, RT-S2, RT-S3, DT, and PVT. Consequently, these are
the only parameters that provided noninferiority limits for the present
study. The clinical relevance of neurocognitive tests used in the pre-
sent study will only be discussed for these parameters.
All statistical analyses were conducted by using the IBM Statisti-
cal Package for the Social Sciences for Windows (Version 24.0.01.,
IBM Corp., Armonk, NY, USA). Power calculations were performed
using G*Power Version 3.1 (Faul, Erdfelder, Lang, & Buchner, 2007).
3 | RESULTS
3.1 | Group characteristics
Table 1 summarizes the characteristics of the patient groups and con-
trol group. Age, gender, and driving experience did not differ signifi-
cantly between groups. As expected, patients had on average more
complaints of anxiety, depression, and sleep problems compared with
F IGURE 2 Schedule of a testing day. Time (in hours) is displayed
relative from start. ATTPT, Adaptive Tachistoscopic Traffic Perception
Test; DSST, Digit Symbol Substitution Test; DT, Determination Test;
PVT, Psychomotor Vigilance Test; RT, Reaction Test; RTTT, Risk-
Taking Test Traffic; TMT, Trail Making Test
F IGURE 3 Hypothetical example of the qualification of clinical
relevance of performance differences between patients and controls.
The dotted line indicates the change in performance after alcohol
intake (relative to placebo). A (drug induced) change in performance
will be classified as inferior when the 95% confidence interval
(CI) includes the alcohol criterion but not zero (A—inferiority).
Noninferiority is concluded when the 95% CI does not include the
alcohol criterion (B—noninferiority). If the 95% CI includes the alcohol
criterion as well as zero, the qualification of clinical relevance is
undecided (C—inconclusive). BAC, blood alcohol concentration
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controls. Differences in scores on BDI, STAI-T, PSQI, and GSQS were
significant for anxiolytic and hypnotic users, as well as for the hyp-
notic LT3− and LT3+ subgroups (all ps < .01).
Table 2 gives an overview of psychoactive medication used per
patient group. All participants took their medication at least
4 days/week. Users of anxiolytics indicated they used their medica-
tion daily, and users of hypnotics reported medication use at least
four nights per week. In total, 30 patients used psychoactive
comedication (Table 2), mostly second-generation antidepressants
(n = 22) and second-generation antipsychotics (n = 6). Most antide-
pressants were selective serotonin reuptake inhibitors and serotonin–
norepinephrine reuptake inhibitors, which have minor effects on driv-
ing (Category I). Second-generation antipsychotics can have moderate
effects on driving (Category II). The proportion of patients using cate-
gory II comedication was higher in the LT3− group (44%, four out of
nine) than in the LT3+ group (26%, six out of 23) and the anxiolytic
group (25%, three out of 12).
3.2 | Missing data
Data from the highway driving test were missing for one person in the
control group, and for one patient in the hypnotic LT3− subgroup,
due to problems with the recording system.
3.3 | Matching to controls
Analyses showed no significant effect of age, gender, or driving expe-
rience in the analysis of covariance model on SDLP, ATTPT, RTTT,
and PVT mean reaction time. For these parameters, the entire control
group sample was used as a reference for comparison with patient
groups. For the remaining parameters, matched healthy controls were
used for each patient (sub)group.
3.4 | Highway driving test
Mean (±standard error) SDLP of patient (sub)groups and controls is
shown in Figure 4. Mean SDLP of patients using hypnotics differed
significantly from controls, F(1, 93) = 4.12, p = .04. The upper limit of
the 95% CI of this difference (+1.70 cm, 95% CI [+0.04 cm, +3.35 cm])
exceeded the +2.5-cm criterion, indicating clinically relevant impair-
ment. The SDLP of patients using anxiolytics did not significantly dif-
fer from controls, F(1, 74) = 1.50, p = .23. The 95% CI of the mean
difference (+1.48 cm, 95% CI [−0.93 cm, +3.88 cm]) included zero as
well as the +2.5-cm criterion, which indicates that the results are
inconclusive.
Analysis of variance (ANOVA) also showed a significant differ-
ence between LT3− hypnotic users and controls, F(1, 71) = 9.38,
F IGURE 4 Left: mean (±standard error) standard deviation of lateral position (SDLP) for controls and patients groups. Right: mean (95%
confidence interval) differences in SDLP between patient groups and controls. The dotted line indicates the change in performance after alcohol
intake (relative to placebo). Symbols above bars indicate significant difference from controls, p < .05. BAC, blood alcohol concentration
TABLE 1 . Demographic data of patient and control groups
Parameters
Anxiolytic
users (n = 12)
Hypnotic
users (n = 32)
Hypnotics LT3
− (n = 9)
Hypnotics LT3
+ (n = 23)
Controls
(n = 65)
Gender (male/female) 6/6 12/20 2/7 10/13 37/28
Age (years) 55.2 ± 9.6 55.6 ± 12.3 47.8 ± 13.5 58.7 ± 10.6 57.9 ± 10.5
Driving experience (km/year) 11,450 ± 9,050 11,777 ± 9,039 9,594 ± 4,931 12,630 ± 10,177 13,659 ± 9,477
Depression symptoms (BDI) 15.4 ± 12.5 9.2 ± 7.6 11.8 ± 8.4 8.2 ± 7.2 2.5 ± 2.8
Anxiety symptoms (STAI-T) 48.1 ± 11.6 40.4 ± 11.8 44.1 ± 14.4 39.0 ± 10.6 27.1 ± 5.2
Sleep problems (PSQI) 6.6 ± 3.4 10.0 ± 5.4 9.4 ± 6.2 10.2 ± 5.1 2.8 ± 2.4
Sleep complaints pretesting
(GSQS)
4.4 ± 4.6 5.5 ± 4.6 5.3 ± 1.7 5.6 ± 1.0 1.4 ± 1.8
Abbreviations: BDI, Beck's Depression Inventory; GSQS, Groningen Sleep Quality Scale; LT3−, patients treated less than 3 years; LT3+, patients treated
longer than 3 years; PSQI, Pittsburgh Sleep Quality Index; STAI-T, State–Trait Anxiety Index—Trait.
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p < .01, but not between LT3+ hypnotic users and controls,
F(1, 85) = 0.64, p = .43. Mean (95% CI) difference in SDLP between
LT3− patients and controls was +4.56 cm (+1.59 cm, +7.53 cm) and
+0.70 cm (−1.04 cm, +2.44 cm) for LT3+ patients. Noninferiority test-
ing revealed that only for LT3− patient the lower and upper limit of
the mean difference in overall SDLP exceeded zero and the +2.5-cm
criterion, respectively, indicating clinically relevant impairment.
3.5 | Neurocognitive performance
Table 3 shows the mean (±standard error) for all performance parame-
ters for each patient (sub)group and healthy controls and the results
from ANOVA analyses. Table 4 shows an overview of the 95% CI of
mean changes between patients and (matched) controls on alcohol-
sensitive parameters only, including inferiority limits and analyses.
Comparisons between patients using anxiolytics and controls showed
significant impairment of patients' performance on the DT and
PVTMeanRT. The 95% CI of mean changes in reaction time in the DT
and PVT was above zero and exceeded the BAC of 0.5-mg/ml crite-
rion, indicating clinically relevant impairment.
ANOVA showed significant performance differences between
patients using hypnotics and controls in the TMT-B, DSST, RT-S1
(motor and reaction time), RT-S2 (motor and reaction time), RT-S3
(motor and reaction time), DT, RTTT, and mean reaction time in PVT.
Noninferiority analysis of alcohol-sensitive parameters showed that
the 95% CIs of differences in DSST, RT-S1, RT-S2, RTS3, and PVT
exceeded zero and the alcohol criterion indicating that impairment on
these parameters can be considered clinically relevant.
ANOVA showed significant performance differences between
LT3− hypnotic users and controls in the DSST, RT-S1 (motor time),
RT-S2 (motor and reaction time), RT-S3 (reaction time), DT, and
PVT mean reaction time. Noninferiority analysis showed that the
95% CIs of differences in DSST, RT-S2, RT-S3, DT, and PVT
exceeded zero and the alcohol criterion indicating clinically relevant
impairment.
ANOVA revealed significant performance differences between
LT3+ hypnotic users and controls in the TMT-B, DSST, RT-S1 (motor
time), RT-S3 (motor time), DT, RTTT, and PVT mean reaction time.
Noninferiority analysis showed that the 95% CIs of differences in
DSST, DT, and PVT exceeded zero and the alcohol criterion indicating
impairment.
TABLE 2 . Psychoactive medication used per group (reported dosages in mg)
Group Comedication
Benzodiazepine M ± SD N Category I M ± SD N Category II M ± SD N
Anxiolytic users (n = 12)
Alprazolam, b.i.d. 1.0 ± 0.7 2 (Es)citalopram 13.3 ± 5.8 3 Clomipramine 50.0 1
Bromazepam, q.d. 3.0 2 Fluoxetine 10.0 1 Olanzapine 10.0 1
Lorazepam, t.i.d. 0.75 ± 0.4 2 Paroxetine 23.0 ± 24.0 2 Oxycodone 45.0 1
Oxazepam, b.i.d./t.i.d. 10.4 ± 2.5 6 Venlafaxine 119 ± 8.8 2 Quetiapine 150.0 1
Hypnotic users, LT3− (n = 9)
Lorazepam, nocte 1.0 2 (Es)citalopram 30.0 ± 11.5 4 Duloxetine 60.0 1
Lormetazepam, nocte 2.0 1 Fluoxetine 30.0 1 Lithium 900.0 ± 141.4 2
Midazolam, nocte 3.75 1 Sertraline 100.0 1 Quetiapine 50.0 1
Temazepam, nocte 20.0 ± 8.2 4 Risperidone 2.0 1
Zolpidem, nocte 10.0 1
Hypnotic users, LT3+ (n = 23)
Brotizolam, nocte 0.25 1 Cetirizine 10.0 1 Duloxetine 30.0 1
Diazepam, nocte 5.0 1 Citalopram 17.5 ± 5 4 Lamotrigine 10.0 1
Lorazepam, nocte 1.1 ± 0.1 3 Fluoxetine 40.0 1 Oxycodone 10.0 1
Lormetazepam, nocte 3.0 1 Methylphenidate 30.0 1 Pramipexol 0.35 1
Midazolam, nocte 15.0 1 Paroxetine 20.0 3 Pregabalin 75.0 1
Nitrazepam, nocte 4.4 ± 0.9 2 Quetiapine 237.5 ± 300.5 2
Oxazepam, nocte 17.5 ± 9.6 4 Tranylcypromine 80.0 1
Temazepam, nocte 15.0 ± 7.1 2
Zolpidem, nocte 11.7 ± 2.9 3
Zopiclone, nocte 7.5 5
Abbreviations: b.i.d., twice a day; LT3−, patients treated less than 3 years; LT3+, patients treated longer than 3 years; nocte, bedtime administration; q.d.,
once a day; t.i.d., three times a day.
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4 | DISCUSSION
This study aimed to compare driving performance of long-term users
of benzodiazepine or benzodiazepine-related anxiolytics and hyp-
notics to that of a normative control group consisting of healthy vol-
unteers, in order to evaluate whether classification of these drugs in
Category III may be too conservative for patients who receive long-
term treatment. Overall, mean SDLP was significantly higher in
patients treated with hypnotics as compared with controls, indicating
their driving performance is worse than normal. This seemed mainly
due to patients who had been using hypnotic less than 3 years, as the
difference in SDLP form controls was significant in this group but not
in those who had received hypnotics treatment for more than 3 years.
Mean SDLP did not differ significantly between patients treated with
anxiolytics and controls, which may be explained by a lack of power
due to the small sample size and large individual variation. Both
patient groups (users of hypnotics and anxiolytics) displayed increased
reaction times in a number of neurocognitive tasks. In line with find-
ings for SDLP in hypnotic users, these impairments were most promi-
nent in patients who used these drugs for less than 3 years. Clinical
relevance seemed less present in patients using hypnotics for more
than 3 years.
The clinical relevance of the effects of long-term benzodiaze-
pines use on driving ability and neurocognitive performance was
determined by comparing the average difference in performance
between patients and controls with the change in performance in
subjects who were under the influence of a BAC of 0.5 mg/ml, the
legal limit for driving under the influence of alcohol in many coun-
tries. Previous studies employing the on-the-road highway driving
test have demonstrated an average increase in mean SDLP of
TABLE 3 . Mean (±standard error) of all performance parameters for each patient group and the (matched) healthy control group and results
from analysis of variance
All controls Anxiolytics Hypnotics Hypnotics LT3− Hypnotics LT3+ All controls
N = 12 N = 32 N = 9 N = 23 N = 65
SDLP (cm) 19.3 ± 1.1 19.5 ± 0.7* 22.4 ± 1.4* 18.5 ± 0.8 17.8 ± 0.5
ATTPT (number correct) 94.1 ± 3.6 96.0 ± 2.1 96.7 ± 4.1 95.8 ± 2.5 98.0 ± 1.5
RTTT 7.9 ± 0.4 7.1 ± 0.3* 8.3 ± 0.5 6.6 ± 0.3* 7.9 ± 0.2














N = 12 N = 11 N = 32 N = 24 N = 9 N = 6 N = 23 N = 18
TMT-A (s) 34.5 ± 3.3 31.5 ± 3.5 35.2 ± 2.1 29.9 ± 2.4 29.3 ± 2.6 30.3 ± 3.2 37.5 ± 2.7 29.8 ± 3.0
TMT-B (s) 72.7 ± 9.5 61.7 ± 10.0 77.3
± 5.6*
59.4 ± 6.3 65.0 ± 11.1 51.1 ± 13.6 82.4 ± 6.4* 62.1 ± 7.1
DSST (number
correct)
52.3 ± 3.1 57.0 ± 3.2 53.5
± 1.8*




280 ± 112 273 ± 12 303 ± 10* 265 ± 12 331 ± 28 270 ± 34 291 ± 10 263 ± 10




217 ± 9 223 ± 10 257 ± 10* 225 ± 12 285 ± 20* 213 ± 25 246 ± 11 230 ± 13




431 ± 20 437 ± 12 490 ± 17* 429 ± 19 534 ± 32* 418 ± 39 473 ± 19 433 ± 22
Motor time (ms) 181 ± 20 179 ± 20 229 ± 13* 167 ± 15 243 ± 31 142 ± 39 224 ± 13* 176 ± 15
DT reaction time
(ms)
963 ± 34* 836 ± 36 942 ± 21* 833 ± 25 932 ± 41* 787 ± 50 946 ± 25* 848 ± 28
PVT Lapses
(number)
3.2 ± 0.7 1.4 ± 0.7 3.3 ± 0.8 1.8 ± 0.9 4.9 ± 2.8 1.0 ± 3.2 2.7 ± 0.6 2.1 ± 0.7
Abbreviations: ATTPT, Adaptive Tachistoscopic Traffic Perception Test; DSST, Digit Symbol Substitution Test; DT, Determination Test; LT3−, patients
treated less than 3 years; LT3+, patients treated longer than 3 years; PVT, Psychomotor Vigilance Test; RT, Reaction Test; RTTT, Risk-Taking Test Traffic;
SDLP, standard deviation of lateral position; TMT, Trail Making Test.
*Indicates significant difference from (matched) control group.
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2.5 cm in drivers operating with a BAC level of 0.5 mg/ml (Jongen
et al., 2017). In the present study, the mean increase in SDLP in
patients using anxiolytic or hypnotic drugs was 1.48 and 1.70 cm,
respectively, relative to healthy controls. The 95% CI of these
mean differences included the alcohol criterion in both groups, as
well as zero in case of the anxiolytic users. As mentioned above,
driving performance of anxiolytic users was inconsistent. Some indi-
viduals showed marked increments in SDLP, whereas others did
not. Overall, no conclusion can be drawn for this group from
these data.
Driving impairment observed in hypnotic users is of clinical rele-
vance, because it exceeds the level of impairment associated with the
legal limit of alcohol in traffic. This is in line with results from epidemi-
ological studies showing increased risk of traffic accidents associated
with the use of hypnotics (Gustavsen et al., 2008; Hansen et al., 2015;
Orriols et al., 2011). Interestingly, however, severe impairment was
present only in patients who used hypnotics less than 3 years,
whereas no relevant impairment, as measured by SDLP, was found in
those who had been using hypnotics longer than 3 years. The mean
difference in SDLP between controls and hypnotic LT3− users was
+4.56 cm, which is equivalent to a BAC > 0.8 mg/ml (Louwerens et al.,
1987). For LT3+ users, the mean difference was only 0.70 cm, and the
95% CI remained below the alcohol criterion, indicating no relevant
impairment of driving. The latter finding is in line with that from a pre-
vious driving study in insomnia patients who frequently used hyp-
notics (Leufkens, Ramaekers, de Weerd, Riedel, & Vermeeren, 2014).
Duration of use in these patients was on average 7.7 years, and their
SDLP did not differ from those of a group of normal sleepers. The
difference in impairment between the LT3− and LT3+ groups in our
study corresponds with gradually decreasing accident risk found in
epidemiological studies following benzodiazepine treatment (Neutel,
1995; Verster et al., 2005). Although development of physiological
tolerance may explain the mitigation in impairment, other factors may
also play a role, such as improvements in underlying conditions, reduc-
tion in comedication, and behavioural tolerance (i.e., learning to mini-
mize unwanted drug effects on performance by cognitive or
behavioural adaptations).
Users of hypnotics and anxiolytics also demonstrated increments
of reaction times as compared with controls on a number of
neurocognitive tasks that exceeded the alcohol criterion of clinical rel-
evance. In line with the results of the driving test, results of cognitive
tests were mostly inconclusive for users of anxiolytics and showed
clinically relevant impairment in users of hypnotics. Similar to driving
impairment, psychomotor impairment in hypnotic users was most
severe in patients who had been using these drugs less than 3 years.
Contrary to the absence of driving impairment, patients who used
hypnotics longer than 3 years showed relevant impairment in some
tests (i.e., the PVT, DSST, and DT). This finding seems in line with
recent reviews (Crowe & Stranks, 2017; van der Sluiszen, Vermeeren,
Jongen, Vinckenbosch, & Ramaekers, 2017) concluding that long-term
treatment with benzodiazepines can be associated with deleterious
neuropsychological effects. Impairment was even found to persist fol-
lowing benzodiazepine withdrawal (Crowe & Stranks, 2017). The
question remains what the consequences of this impairment are for
driving. From the alcohol calibration of our tests, we can conclude that
the impairment found in some neurocognitive tests after 3 years of













TMT-A (s) +2.72 +2.9 (−7.1, +12.9) Inc +5.3 (−1.2,
+11.7)















Reaction time (ms) +10.35 +6 (−28, +41) Inc +38 (+6, +70) Inf +62 (−34, +157) Inc +28 (−1, +58) Inc
RT-S2
Reaction time (ms) +7.83 −6 (−35, +22) Inc +32 (+1, +62) Inf +72 (+2, +141) Inf +17 (−18,+51) Inc
RT-S3
Reaction time (ms) +23.82 −7 (−68, +55) Inc +62 (+11, +112) Inf +116 (+8, +224) Inf +40 (−18, +99) Inc
DT
Reaction time (ms) −9.14 +127 (+25, +229) Inf +109 (+44,
+175)
Inf +146 (+5, +286) Inf +98 (+21, +175) Inf
PVT
Mean RT (ms) +19.36 +39 (+15, +64) Inf +22 (+6, +39) Inf +31 (+2, +60) Inf +20 (+4, +35) Inf
Lapses (number) +1.71 +1.8 (−0.3, +3.9) Inc +1.4 (−1.1, +3.9) Inc +3.9 (−5.3,
+13.1)
Inc +0.6 (−1.3, +2.4) Inc
Abbreviations: DSST, Digit Symbol Substitution Test; DT, Determination Test; Inc, inconclusive; Inf, inferiority; LT3−, patients treated less than 3 years;
LT3+, patients treated longer than 3 years; PVT, Psychomotor Vigilance Test; RT, Reaction Test; TMT, Trail Making Test.
10 of 13 VAN DER SLUISZEN ET AL.
hypnotic use is comparable with, or larger than, the effects found for
alcohol at a BAC of 0.5 mg/ml. It can be concluded that impairment
may be moderate, but the evidence that patients who have been using
hypnotics more than 3 years are severely impaired is weak. So the
current classification, and the associated general prohibition to drive
when using these drugs, may be too strict for this group of patients.
For shorter use of hypnotics, our data support the current classifica-
tion as Category III. For anxiolytics, there is no evidence to support a
change in the current classification.
Several limitations may be present in this study. First, there
may be a selection bias, in so far as probably only patients who
estimated themselves as fit to drive volunteered for the study.
However, these patients may be representative for the target pop-
ulation, that is, long-term users who are active car drivers. Patients
who do not feel fit to drive are less likely to drive in real life. Sec-
ond, it should be noted that the statistical power to detect clini-
cally relevant impairment was much less in anxiolytic users (n = 12)
and hypnotic LT3− users (n = 9), due to the low sample size in
both groups. Yet differences from controls were relatively large in
the LT3− group and therefore still achieved statistical significance.
Third, the anxiolytic and hypnotic users in the present study
formed a heterogeneous sample due to the diversity in benzodiaze-
pines, daily dosages, time since last dosage, and comedication. Such
factors may generate variability in performance between patients
and hinder the interpretation of underlying mechanisms. However,
it does reflect the diversity in the population of long-term users of
benzodiazepines who drive a car. Fourth, subdivision of benzodiaz-
epine use below and above 3 years was a legislative measure as
adopted in the Netherlands. Strict conclusions based on this subdi-
vision should therefore be avoided. Nonetheless, future studies
could explore the time needed to build op tolerance to the
impairing effects of daily antidepressant usage and handle treat-
ment duration as a continuous variable over time.
Overall, the results show that impairing effects of benzodiazepine
hypnotics on driving performance may mitigate over time following
long-term use of 3 years, although forms of neurocognitive impair-
ment may remain. This supports the idea to take duration of treat-
ment into account when evaluating the impact of hypnotics on
individual drivers. The implication would be that classification systems
that grade effects of drugs on driving should allow for differential clas-
sification of hypnotics in relation to treatment duration. The results
do not support differential grading for benzodiazepine anxiolytics.
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